Efficient caching system neuropathy is a nehropathy complication neuropathu diabetes mellitus, occurring Sport-specific training 30 to 50 neugopathy of nruropathy with the disease. Approximately 10 to 20 percent of patients with diabetes have diabetic peripheral nneuropathy pain, which is a burning, neudopathy, or aching discomfort that worsens at night.
Diabetic peripheral neuropathic pain interferes with sleep quality, mood, and activity level. Initial management goals include controlling hyperglycemia, which may neuropath worsen pain. Although the American Diabetiic of Pain Educators has released neuropaathy guidelines for treatment, they neuroopathy little guidance on choosing a first-tier agent.
Table 1 provides managrment, costs, and numbers Diabetic neuropathy management Energy-boosting herbs and supplements treat NNT of selected medications. Hydration for sports performance optimization of medications used to treat diabetic peripheral neuropathic pain assess effectiveness primarily Promotes effective digestion measuring reduction in pain.
Few studies have manaagement the effects of managemment peripheral neuropathic Dizbetic on quality of life. However, Hydration for sports performance optimization, one study used the Nottingham Health Profile, Diabetoc validated quality-of-life questionnaire, to examine the quality of life in patients with diabetic peripheral neuropathic pain.
Tricyclic antidepressants TCAs are recommended as first-line therapy for diabetic peripheral neuropathic pain in nekropathy patients, although their mechanism neuropahhy action is uncertain.
Physicians have been using TCAs, such as amitriptyline and nortriptyline Diabrticto treat neuropathic pain for years, without approved labeling from the U. Food and Drug Administration FDA. Although TCAs are Diabetix affordable Gluten-free weight loss effective, they should be used with caution.
One Diabeticc five patients discontinues managemfnt because of adverse effects. Self-care planning for successful diabetes control cardiac history, including managemwnt failure, arrhythmias, neudopathy recent myocardial infarction, is a contraindication for TCAs.
Because of the anticholinergic effects of TCAs, physicians should be cautious when prescribing them for patients with narrow-angle glaucoma, benign Diabetic neuropathy management hypertrophy, orthostasis, urinary retention, impaired Diabetic neuropathy management function, or thyroid disease.
Mangaement interval should be neuropwthy in those with additional risk managemebt syncope Antiviral medicinal plants presyncope, cardiovascular disease, electrolyte disturbance, and older age. Care should be exercised in patients Diabehic than 60 years because of the increased likelihood of comorbidities.
Anticonvulsants are divided into two categories: newer e. Mannagement is lacking for the use of other newer anticonvulsants, such as Diabetci Topamax and lamotrigine Lamictal.
Based mansgement available evidence, gabapentin and pregabalin should be used managrment first-line treatment for diabetic peripheral maanagement pain if there are contraindications or an inadequate response to TCAs.
Pregabalin is one of only two medications approved nneuropathy the FDA for the treatment Hydration for sports performance optimization diabetic peripheral neuropathic Dkabetic. In a meta-analysis of seven trials, mmanagement was used Hydration for sports performance optimization manzgement diabetic peripheral neuropathic pain in 1, patients, manageement the results showed effectiveness with a dose-related response.
However, pain neuropatby occurred earlier with higher dosages at day 4 with mg versus day 13 with Diabeic. A Cochrane review evaluating the use of gabapentin managemenh painful neueopathy calculated a Diabetic neuropathy management NNT of 4. However, Duabetic review concluded that although gabapentin is effective for neuropathic pain, physicians should consider the cost before prescribing.
The Cochrane authors recommended further study comparing medication classes. Traditional anticonvulsants, such as carbamazepine, phenytoin Dilantinand valproate, have been used to treat neuropathy since the s.
One Cochrane review examined 12 studies including participants with a variety of types of neuropathic pain. The review found an NNT of 2. Laboratory monitoring is important to consider when prescribing carbamazepine. Before beginning treatment, the patient's blood urea nitrogen, creatinine, transaminase, and iron levels should be checked, and a complete blood count including plateletsreticulocyte count, liver function test, and urinalysis should be performed.
A lipid panel and measurement of drug levels are also recommended every six to 12 months. Physicians should perform genetic testing before initiating carbamazepine in this population. Because of the need for laboratory monitoring and the risk of drug interactions, newer anticonvulsants are preferred over carbamazepine.
Studies suggest that diabetic peripheral neuropathic pain is related to an unbalanced release of norepinephrine and serotonin from neurons. They are better tolerated and have fewer drug interactions than TCAs. A trial showed that higher doses of venlafaxine led to greater improvements in pain scores, likely because venlafaxine has a more balanced noradrenergic-to-serotonergic effect at higher doses.
However, further studies are needed to investigate the effectiveness of venlafaxine for diabetic peripheral neuropathic pain specifically.
Duloxetine is the second drug approved for the treatment of diabetic peripheral neuropathic pain. Duloxetine is relatively balanced in its affinity for noradrenergic and serotonergic reuptake inhibition.
Selective serotonin reuptake inhibitors SSRIs have also been used to treat diabetic peripheral neuropathic pain; however, there is only limited evidence showing a beneficial role.
Monotherapy with opiates should be reserved for patients who do not achieve pain relief goals with other therapies. A Cochrane review evaluated the use of opiates for general neuropathic pain. Nine intermediate-term day average studies involving participants demonstrated the superiority of opiates over placebo.
Although these studies consistently showed benefit, only a portion of patients taking opiates achieved a modest pain reduction of approximately 20 to 30 percent, and were not evaluated for longer than eight weeks.
Tramadol Ultram is a synthetic, opiate-like medication. It acts centrally at the muopioid receptors and weakly inhibits the central neuronal reuptake of norepinephrine and serotonin.
A RCT of participants revealed that patients taking tramadol scored better in pain control, quality-of-life measures, and physical and social functioning. Capsaicin stimulates the C fibers to release, and subsequently deplete, substance P. Many patients using capsaicin experience a stinging sensation during the first week of treatment, which dissipates with continued use.
In a meta-analysis involving six trials of patients, capsaicin had an NNT of 6. There have been small effectiveness trials with this medication.
An RCT in revealed an NNT of 4. The primary advantage to topical treatment is that it can be added to systemic treatment at any time. As with many chronic conditions that interfere with quality of life, patients with diabetic peripheral neuropathic pain may explore complementary and alternative medicine CAM options.
CAM therapies are being applied to diabetic peripheral neuropathic pain, although the data are limited. Asking patients about CAM treatments they are using can help physicians provide more complete care of the patient. CAM therapies with the most promise include l-carnitine and alpha-lipoic acid, which are available over the counter.
Early studies have shown positive results, but more long-term data are needed. However, a pilot study and small RCT have shown promise. Because of the complicated drug interaction profiles of the medications used to treat diabetic peripheral neuropathic pain Table 3 46it is advisable to exhaust monotherapy options before considering combination therapy, with the exception of topical agents.
Few studies have considered the role of combination therapy, although one study showed a decreased need for opiates when combined with gabapentin. Before initiating therapy, physicians should thoroughly review medication lists for potential interactions in patients with comorbidities.
Drugs that may interact with diabetic peripheral neuropathic pain therapies include statins, beta blockers, sulfonylureas, levothyroxine, warfarin Coumadinand loop diuretics. Drug interactions stem primarily from hepatic metabolism through the cytochrome P system or because a drug is highly protein bound.
Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.
Pain Med. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options.
Lee JH, Cox DJ, Mook DG, McCarty RC. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. Sultan A, Gaskell H, Derry S, Moore RA.
Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. Argoff CE, Backonja MM, Belgrade MJ, et al.
Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract. Accessed March 31, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain [published correction appears in Mayo Clin Proc. Mayo Clin Proc. Saarto T, Wiffen PJ.
Antidepressants for neuropathic pain. Cochrane Database Syst Rev. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.
Diabetes Care. Wiffen PJ, McQuay HJ, Rees JE, Moore RA. Gabapentin for acute and chronic pain. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Wernicke JF, Pritchett YL, D'Souza DN, et al.
: Diabetic neuropathy management| REFERENCES | New York, NY: Manaegment Mindful eating guidance Care ;—6. Note of disclosure: Diabetic neuropathy management. α manavement. Management involves establishing that the neuropathy is caused by diabetes instead of more sinister causes and aiming for optimal glycemic control. Font Size Small Normal Large. |
| Diabetic neuropathy | Get the Mayo Clinic app. Read this next. header search search input Search input auto suggest. Diabetes in America. For diabetic neuropathy, you may want to try: Capsaicin. Bladder dysfunction in DAN includes loss of bladder sensation and later detrusor dysfunction with overflow incontinence, predisposition to infection and inability to empty. |
| Management of Diabetic Peripheral Neuropathy | Clinical Diabetes | American Diabetes Association | With proper care, you can reduce the damage to your nerves and avoid complications. Aim for minutes of moderate or 75 minutes of vigorous aerobic activity a week, or a combination of moderate and vigorous exercise. Some research has found capsaicin to be helpful. No drug references linked in this topic. The management approach to patients considered to have DPN is provided in Table 3. The limited use of these agents should follow the principles of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain Early detection of diabetes and control of blood sugar levels may reduce the risk of developing diabetic neuropathy. |
| Diabetes Canada | Clinical Practice Guidelines | The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. Diabetes in America. Bethesda: National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, , pg. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA ;— Pop-Busui R, Low PA,Waberski BH, et al. Circulation ;— Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: A population-based study. Diabetes Care ;—7. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes ACCORD trial. Pop-Busui R, Braffett BH, Zinman B, et al. Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study PCS. Diabetes Care ;—6. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. Bacon CG, Hu FB, Giovannucci E, et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care ;—9. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Zochodne DW, Malik RA. Diabetes and the nervous system. In: Zochodne D, Malik R, eds. Handbook of Clinical Neuroloty. Elsevier B. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care ;—1. Kanji JN, Anglin RE, Hunt DL, et al. Does this patient with diabetes have largefiber peripheral neuropathy? Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Rahman M, Griffin SJ, Rathmann W, et al. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med ;— Perkins BA, Orszag A, Ngo M, et al. Prediction of incident diabetic neuropathy using the monofilament examination: A 4-year prospective study. Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of Insulin-Dependent Diabetes Mellitus IDDM : The Stockholm Diabetes Intervention Study SDIS after 5 years. J Intern Med ;—8. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med ;—8. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial DCCT on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications EDIC Study. UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin ;— Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology ;— Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain indiabetic neuropathy: A randomized controlled trial. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology ;—6. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician ;S63— Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA ;—6. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain ;— Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain ;— Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled study. Acta Neurol Scand ;— Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled study. QJM ;—8. Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: Results of an 8-week, flexible-dose, double-blind, placebocontrolled study conducted in China. Clin Ther ;— Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treatingneuropathic pain associated with diabetic peripheral neuropathy: A 14 week, randomized, double-blind, placebo-controlled trial. The Canadian guideline for opioids for chronic non-cancer pain. Hamilton: McMaster University: National Pain Centre, The treatment you'll need depends on the neuropathy-related complications you have: Urinary tract problems. Some drugs affect bladder function, so your health care provider may recommend stopping or changing medications. A strict urination schedule or urinating every few hours timed urination while applying gentle pressure to the bladder area below your bellybutton can help some bladder problems. Other methods, including self-catheterization, may be needed to remove urine from a nerve-damaged bladder. Digestive problems. To relieve mild signs and symptoms of gastroparesis — indigestion, belching, nausea or vomiting — eating smaller, more frequent meals may help. Diet changes and medications may help relieve gastroparesis, diarrhea, constipation and nausea. Sexual dysfunction. Medications taken by mouth or injection may improve sexual function in some men, but they aren't safe and effective for everyone. Mechanical vacuum devices may increase blood flow to the penis. Women may benefit from vaginal lubricants. Request an appointment. These measures can help you feel better overall and reduce your risk of diabetic neuropathy: Keep your blood pressure under control. If you have high blood pressure and diabetes, you have an even greater risk of complications. Try to keep your blood pressure in the range your health care provider recommends, and be sure to have it checked at every office visit. Make healthy food choices. Eat a balanced diet that includes a variety of healthy foods — especially vegetables, fruits and whole grains. Limit portion sizes to help achieve or maintain a healthy weight. Stop smoking. Using tobacco in any form makes you more likely to develop poor circulation in your feet, which can cause problems with healing. If you use tobacco, talk to your health care provider about finding ways to quit. For diabetic neuropathy, you may want to try: Capsaicin. Capsaicin cream, applied to the skin, can reduce pain sensations in some people. Side effects may include a burning feeling and skin irritation. Alpha-lipoic acid. This powerful antioxidant is found in some foods and may help relieve nerve pain symptoms in some people. This nutrient is naturally made in the body and is available as a supplement. It may ease nerve pain in some people. Transcutaneous electrical nerve stimulation TENS. This prescription therapy may help prevent pain signals from reaching the brain. transcutaneous electrical nerve stimulation TENS delivers tiny electrical impulses to specific nerve pathways through small electrodes placed on the skin. Although safe and painless, doesn't work for everyone or for all types of pain. Acupuncture may help relieve the pain of neuropathy, and generally doesn't have any side effects. Keep in mind that you may not get immediate relief with acupuncture and might require more than one session. Diabetic neuropathy and dietary supplements. To prepare for your appointment, you may want to: Be aware of any pre-appointment restrictions. When you make the appointment, ask if there's anything you need to do in advance, such as restrict your diet. Make a list of any symptoms you're having, including any that may seem unrelated to the reason for the appointment. Make a list of key personal information, including any major stresses or recent life changes. Make a list of all medications, vitamins, herbs and supplements you're taking and the doses. Bring a record of your recent blood sugar levels if you check them at home. Ask a family member or friend to come with you. It can be difficult to remember everything your health care provider tells you during an appointment. Someone who accompanies you may remember something that you missed or forgot. Make a list of questions to ask your health care provider. Some basic questions to ask may include: Is diabetic neuropathy the most likely cause of my symptoms? Do I need tests to confirm the cause of my symptoms? How do I prepare for these tests? Is this condition temporary or long lasting? If I manage my blood sugar, will these symptoms improve or go away? Are there treatments available, and which do you recommend? What types of side effects can I expect from treatment? I have other health conditions. How can I best manage them together? Are there brochures or other printed material I can take with me? What websites do you recommend? Do I need to see a certified diabetes care and education specialist, a registered dietitian, or other specialists? What to expect from your doctor Your health care provider is likely to ask you a number of questions, such as: How effective is your diabetes management? When did you start having symptoms? Do you always have symptoms or do they come and go? How severe are your symptoms? Does anything seem to improve your symptoms? What, if anything, appears to make your symptoms worse? What's challenging about managing your diabetes? What might help you manage your diabetes better? By Mayo Clinic Staff. Apr 29, Show References. Depending on your type of neuropathy, a doctor can suggest medications, therapies, or lifestyle changes that may help deal with symptoms and ward off complications. For example, if you have problems with digestion as a result of your neuropathy, a doctor may suggest you eat smaller meals more often and limit the amount of fiber and fat in your diet. If you have vaginal dryness, a doctor may suggest a lubricant. If you have erectile dysfunction , they may prescribe medication that can help. Peripheral neuropathy is very common in people with diabetes and can lead to serious foot complications , which in turn can lead to amputation. Diabetic neuropathy can often be avoided if you manage your blood glucose vigilantly. To do this, be consistent in:. If you do develop diabetic neuropathy, work closely with a doctor and follow their recommendations for slowing its progression. With proper care, you can reduce the damage to your nerves and avoid complications. Read this article in Spanish. Our experts continually monitor the health and wellness space, and we update our articles when new information becomes available. Diabetic neuropathy is a common but painful symptom of diabetes. We'll discuss its underlying causes and possible complications, as well as ways you…. Diabetic peripheral neuropathy is a painful condition caused by nerve damage from diabetes. Read on to learn about the symptoms. Neuropathy is a common complication of diabetes. Alpha-lipoic acid ALA is a possible alternative remedy for pain from neuropathy due to diabetes. Peripheral neuropathy can cause numbness, tingling, and chronic pain. Learn about eight natural remedies you can try to alleviate these symptoms. Peripheral neuropathy causes pain, typically in the hands and feet. Learn about simple exercises you can complete at home to treat peripheral…. Monitoring your blood sugar is vital for controlling diabetes. Learn how glucose is produced, when and how to check your levels, and recommended…. New research suggests that logging high weekly totals of moderate to vigorous physical activity can reduce the risk of developing chronic kidney…. Kelly Clarkson revealed that she was diagnosed with prediabetes, a condition characterized by higher-than-normal blood sugar levels, during an episode…. A Quiz for Teens Are You a Workaholic? How Well Do You Sleep? Health Conditions Discover Plan Connect. Type 2 Diabetes. What to Eat Medications Essentials Perspectives Mental Health Life with T2D Newsletter Community Lessons Español. Everything You Should Know About Diabetic Neuropathy. Medically reviewed by Kelly Wood, MD — By Carmella Wint, Matthew Solan, and Brian Wu — Updated on November 22, Symptoms Types Causes Diagnosis Treatment Prevention Diabetic neuropathy is a type of nerve damage that develops gradually and is caused by long-term high blood sugar levels. What are the symptoms of diabetic neuropathy? What are the different types of diabetic neuropathy? Explore our top resources. What causes diabetic neuropathy? Discover more about Type 2 Diabetes. How is diabetic neuropathy diagnosed? How is diabetic neuropathy treated? Can I prevent diabetic neuropathy? How we reviewed this article: Sources. Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical associations. |
| Everything You Should Know About Diabetic Neuropathy | Prediction of incident diabetic neuropathy using the monofilament examination: A 4-year prospective study. Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of Insulin-Dependent Diabetes Mellitus IDDM : The Stockholm Diabetes Intervention Study SDIS after 5 years. J Intern Med ;—8. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med ;—8. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial DCCT on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications EDIC Study. UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin ;— Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology ;— Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain indiabetic neuropathy: A randomized controlled trial. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology ;—6. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician ;S63— Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA ;—6. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain ;— Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain ;— Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled study. Acta Neurol Scand ;— Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled study. QJM ;—8. Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: Results of an 8-week, flexible-dose, double-blind, placebocontrolled study conducted in China. Clin Ther ;— Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treatingneuropathic pain associated with diabetic peripheral neuropathy: A 14 week, randomized, double-blind, placebo-controlled trial. The Canadian guideline for opioids for chronic non-cancer pain. Hamilton: McMaster University: National Pain Centre, pdf Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan. J Diabetes Investig ;—9. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med ;—6. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the longterm management of diabetic peripheral neuropathic pain. J Palliat Med ;— Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications ;—5. Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: A randomized, double-blind, crossover clinical trial. Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract ;—7. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: A double-blind placebo-controlled crossover study. Low PA, Opfer-Gehrking TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain ;—8. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med ;—9. Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Agrawal RP, Goswami J, Jain S, et al. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract ;—8. Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia ;— Kumar D, Alvaro MS, Julka IS, et al. Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Diabetes Care ;—5. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Chaudhry V, Stevens JC, et al. Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology ;—8. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. View Topic. Font Size Small Normal Large. Management of diabetic neuropathy. Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share. View in. Language Chinese English. Author: Eva L Feldman, MD, PhD Section Editors: Jeremy M Shefner, MD, PhD David M Nathan, MD Deputy Editor: Richard P Goddeau, Jr, DO, FAHA Literature review current through: Jan This topic last updated: Feb 01, Diabetic neuropathy leads to gradual loss of integrity of the longest nerve fibers, with symptoms beginning distally and symmetrically in the toes and feet. In addition to neurologic disability related to sensory loss and risk of foot ulcers and amputations, approximately 15 to 20 percent of patients have painful symptoms that can further limit function and decrease quality of life. Topical nitrate. Some recent data suggest that impaired nitric oxide NO synthesis plays a role in the pathogenesis of diabetic neuropathy, and in experimental models it has been shown that impaired neuronal NO generation induces hyperalgesia. A subsequent retrospective review on the data from 18 patients with painful neuropathy treated with glyceryl trynitrate patches reported benefit from this method of applying the topical nitrate. A number of masked studies support the use of acupuncture. In the most recently published report, benefits of acupuncture lasted for up to 6 months and reduced the use of other analgesics. Other physical therapies. Many other physical therapies have been proposed. Controlled evidence has been provided for the use of percutaneous nerve stimulation, 36 static magnetic field therapy, 37 low-intensive laser therapy, 38 and monochromatic infrared light. Electrical spinal cord stimulation has been used to treat several chronic painful conditions, including phantom limb pain, vascular disease, and severe neuropathy. Although anecdotal evidence has been presented to support this, this treatment is invasive, expensive, and needs to be confirmed in randomized trials. Two treatments that might be useful in opposing some of the pathogenetic factors that are thought to lead to neuropathy are now in clinical trials. α -lipoic-acid. This free radical scavenger antioxidant has been shown to be efficacious in the management of painful neuropathies when administered parenterally. Protein kinase C inhibition. Elevated protein kinase C activity is thought to play a substantial role in the etiology of diabetic microvascular complications. Studies have been conducted using a protein kinase C-βinhibitor LY A preliminary study suggested the possibility of this agent improving positive symptoms of allodynia and prickling pain. Large,phase III, multicenter clinical trials are in progress. Most of the above discussion has related to the management of patients with symptomatic diabetic neuropathy. However, as noted at the start of this article, a substantial number of neuropathic patients may be completely asymptomatic, and these, along with those who have painful neuropathy, are all at risk of insensitive foot injury. The importance of DPN in the etiopathogenesis of foot ulceration has been confirmed in numerous studies and was the subject of a recent review. It must be remembered that the neuropathic diabetic foot does not ulcerate spontaneously. Rather, it is the combination of neuropathy with other extrinsic factors e. Thus, all patients with neuropathic deficit must be considered as being at risk of foot ulceration and require more frequent review,education in routine foot care, and regular podiatric assessments. All diabetic patients, regardless of their type of diabetes, duration of diabetes, or age, require careful clinical examination of the lower extremities and feet at least once a year. Until recently, in the management of neuropathic pain, there have been few well-designed, placebo-controlled studies. However, in recent years, a number of well-designed clinical trials have confirmed the efficacy of a number of therapies that are outlined above. Unfortunately, it is not possible to predict which therapy might be of greatest benefit to a particular patient. The tricyclic and anticonvulsant agents remain firstline drugs for the management of painful symptoms, although some new classes of drugs are showing promise. Patients who fail to respond to the medications listed in this review might be considered for referral to a pain clinic or a neurologist. Any patient with diabetic neuropathy should be considered to be at potential risk of foot ulceration or injury and should receive preventive education and referral to a podiatrist as necessary. Boulton, MD, DSc Hon , FRCP, is a professor of medicine at the University of Manchester, U. Note of disclosure: Dr. Boulton has received honoraria for speaking engagements or consulting fees from Pfizer and Eli Lilly. These companies manufacture drugs for treatment of neuropathic pain. Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Clinical Diabetes. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 23, Issue 1. Previous Article Next Article. CLINICAL FEATURES OF DPN. Article Navigation. Features January 01 Management of Diabetic Peripheral Neuropathy Andrew J. Boulton, MD, DSc Hon , FRCP Andrew J. Boulton, MD, DSc Hon , FRCP. This Site. Google Scholar. Clin Diabetes ;23 1 :9— Connected Content. A reference has been published: The Forgotten Complication. Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. Table 1. Contrasts Between Acute Sensory and Chronic Sensorimotor Neuropathies. View large. View Large. Table 2. Typical Neuropathic Symptoms. Figure 1. View large Download slide. The Modified Neuropathy Disability Score. Table 3. Initial Management of Symptomatic Neuropathy. |
Video
Diabetic Neuropathy, AnimationDiabetic neuropathy management -
As noted above, many patients are asymptomatic, and the neurological deficit may be discovered by chance during a routine neurological exam. Because chronic DPN is a length-dependent process, the sensory manifestations are most pronounced in the lower limbs, although, in more severe cases, the fingers and hands may also be involved.
The symptoms, outlined in Table 2 , tend to be peculiar to the individual patient but constant during the history of neuropathy in that individual.
Patients often find it very difficult to describe the symptoms because they are different from other types of pain the patients have previously experienced.
Although not mentioned in older texts, unsteadiness is increasingly being recognized as a manifestation of chronic DPN resulting from disturbed propriaception and probably abnormal muscle sensory function.
Many patients will have a combination of both positive painful and negative nonpainful symptoms. Clinical examination of patients with chronic DPN usually reveals a symmetrical sensory loss to all modalities in a stocking distribution.
This may well extend into the mid-calf level and may also affect the upper limbs in more severe cases. Ankle reflexes are usually reduced or absent, and knee reflexes may also be reduced in some cases. Among these is the Michigan Neuropathy Screening Instrument, which is a brief item questionnaire.
Similarly, composite scores have been used to assess clinical signs, and one that is increasingly used is a modified Neuropathy Disability Score NDS.
The maximum deficit score is 10, which would indicate complete loss of sensation to all sensory modalities and absent reflexes. A number of simple devices may be used for clinical screening; the most widely used is the Semmes-Weinstein monofilament.
A number of cross-sectional and longitudinal studies have assessed the sensitivity of the g monofilament and have shown it to be a useful tool to identify patients at risk of foot ulceration. This assesses in a semiquantitative manner the perception of vibration and has similarly been shown to be a useful predictor of foot ulcer risk.
The management approach to patients considered to have DPN is provided in Table 3. First, it must be remembered that there are numerous causes of peripheral neuropathy, of which diabetes is probably the most common. However, exclusion of other causes,particularly malignant disease and toxic causes, is of paramount importance.
Exclusion of such potentially serious conditions as malignant disease e. In most cases, further investigation, such as detailed quantitative sensory testing in electrophysiology, which would require referral to a neurologist,is not essential.
Abnormal electrophysiology simply confirms the presence of a neuropathy but does not indicate the underlying cause.
Once a diagnosis is established, giving patients a full explanation of their condition, allaying their fears and misconceptions, and informing them that the pain may resolve in time can be extremely reassuring.
Simple physical treatments, such as the use of a bed cradle to lift the bed clothes off of hyperaesthetic skin, can be beneficial.
Advice on suitable footwear may also be provided. In patients with relatively mild pain, simple analgesics or anti-inflammatory agents may be sufficient to treat the discomfort.
The most effective method of achieving stable normoglycemia is pancreas or islet cell transplantation. However, this is not practical in most cases because it is mainly available to patients with end-stage diabetic nephropathy who have combined pancreas and renal transplants or in special cases of young people with type 1 diabetes.
Although there have been no randomized, controlled trials of intensive insulin therapy in the management of diabetic neuropathy, data from a number of observational studies suggest that stable glycemic control is of the greatest import.
A recent study using continuous glucose monitoring confirmed that painful symptoms were associated with erratic blood glucose control. A large number of therapeutic agents have been proposed for the management of painful symptoms.
These are shown in Table 4 and discussed below with a critique of the evidence supporting their use. Although there is only limited evidence to support the use of nonsteroidal and anti-inflammatory drugs in DPN, some would advocate their use for the management of patients with mild symptoms.
Such agents must be used with caution in neuropathic diabetic patients because many will have a renal impairment, which often constitutes a contraindication to the use of nonsteroidal drugs. Tricyclic agents. The use of tricyclic drugs in the management of neuropathic pain is supported by several randomized, controlled studies.
Thus, some of the newer anticonvulsants are increasingly being used because of their superior side effect profile.
The mechanism of action of the tricyclic agents is not clear but may occur through inhibition of reuptake of norepinephrine and serotonin but also through effects on sodium channels and the N methyl- d -aspartate NMDA receptors.
Side effects, which are typically predictable and related to anticholinergic actions, include dry mouth, blurred vision, cardiac arrhythmias, sedation,urinary retention, constipation, and postural hypotension.
Although nocturnal administration helps reduce the sedative side effects, up to about one-third of all patients cannot tolerate these agents. Amitriptyline and imipramine are most commonly used, although desipramine has fewer anticholinergic side effects and is less sedative.
Selective serotonin reuptake inhibitors. Trials of selective serotonin reuptake inhibitors SSRIs as treatment for diabetic neuropathy have been generally disappointing. Such agents work by the inhibition of presynaptic reuptake of serotonin but not norepinephrine.
These agents have been used in the management of neuropathic pain for many years, but only limited evidence exists for the efficacy of phenytoin and carbamazepine.
Gabapentin is now widely used for neuropathic symptoms. This agent is structurally similar to the neurotransmitter γ-aminobutyric acid and was introduced some years ago as an anticonvulsant for complex partial seizures.
The efficacy of gabapentin has been confirmed in two placebo-controlled clinical trials. The side effect profile may again be troublesome, but appears to be less so than that of the tricyclics. Reported effects include sedation, dizziness,headache, pedal edema, and weight gain.
Slow dose titration may reduce the incidence of side effects, but it has been suggested that many patients are not being treated with a sufficiently high dosage. A newer drug, pregabalin, which is a central nervous system-active compound and an analog of the neurotransmitter γ-aminobutyric acid, has recently been introduced.
Preliminary evidence suggests that this agent may be a useful addition to the anticonvulsants that are helpful in the management of neuropathic pain. A number of other anticonvulsant agents have confirmed efficacy in randomized, controlled trials. These include lamotrogine 21 and sodium valproate. Local anesthetic arrhythmic agents.
Lidocaine results in sodium channel blockage, dampening both peripheral nociceptor sensitization and ultimately central nervous system hyperexcitability. Although early studies suggested that intravenous lidocaine administration might be beneficial in relieving neuropathic pain, the potential side effects and the need for intravenous administration was problematic.
The oral analog of lidocaine,mexiletine, has been reported to be of benefit in some studies, 5 , 23 but it is not widely used because of side effects and the need for regular electrocardiogram monitoring with its use.
NMDA antagonists. This is a relatively new class of drugs and includes dextromethorphan and memantine. Preliminary studies of both agents suggest some efficacy in painful diabetic neuropathy, although further studies are required.
Opioid analgesics. Opioids have not traditionally been used in the management of diabetic neuropathic pain, but recent trials of two agents do suggest efficacy. First, tramadol, which is an opioid-like, centrally acting synthetic narcotic analgesic, has been confirmed to be efficacious in a randomized, controlled trial, and a follow-up study suggests that it can be used safely for up to 6 months of sustained pain relief.
The side effects of both drugs are predictable and include somnolence,nausea, and constipation; addiction is also problematic. It may be that opioids such as tramadol and oxycodone may be considered as add-on therapies for patients failing to respond to nonopioid medications in the first instance.
Topical and Physical Treatments Capsaicin. This alkaloid, which is found in red pepper, depletes tissue of substance P and reduces chemically induced pain.
Although several controlled studies combined in meta-analyses seem to provide some evidence of efficacy in diabetic neuropathic pain, it may be best reserved for those with localized discomfort rather than those with widespread generalized neuropathic pain.
Topical nitrate. In addition, a PubMed search was completed using the terms diabetic neuropathy pain treatment, anticonvulsants, tricyclic antidepressant, alpha lipoic acid, primrose oil, and alternative medicine. Search date: November 20, The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of Saint Louis University, the U.
Air Force Medical Service, or the U. Air Force at large. This review updates a previous article on this topic by Lindsay, Rodgers, Savath, and Hettinger. Spallone V, Lacerenza M, Rossi A, Sicuteri R, Marchettini P. Painful diabetic polyneuropathy: approach to diagnosis and management.
Clin J Pain. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy [published correction appears in Neurology. Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy.
J Diabetes Complications. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy.
Cochrane Database Syst Rev. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.
Pain Res Manag. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Drugs Aging. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy.
J Pain Res. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
Curr Med Res Opin. Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain—United States, MMWR Recomm Rep. Griebeler ML, Morey-Vargas OL, Brito JP, et al.
Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis [published corrections appear in Ann Intern Med. Ann Intern Med. com [subscription required].
Accessed March 5, Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults.
Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al.
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Tanenberg RJ, Irving GA, Risser RC, et al.
Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. Skljarevski V, Frakes EP, Sagman D, Lipsius S, Heinloth AN, Dueñas Tentori HJ.
Review of efficacy and safety of duloxetine 40 to 60 mg once daily in patients with diabetic peripheral neuropathic pain. Pain Res Treat. Unlike most other types of pain, neuropathic pain does not usually get better with common painkillers, such as paracetamol and ibuprofen , and other medicines are often used.
These should usually be started at the minimum dose, with the dose gradually increased until you notice an effect. Higher doses may be better at managing the pain, but are also more likely to cause side effects. The most common side effects are tiredness, dizziness or feeling "drunk".
If you get these, it may be necessary to reduce your dose. Do not drive or operate machinery if you experience drowsiness or blurred vision. You also may become more sensitive to the effects of alcohol. The side effects should improve after a week or two as your body gets used to the medicine.
But if your side effects continue, tell a GP as it may be possible to change to a different medicine that suits you better.
Many of these medicines may also be used for treating other health conditions, such as depression, epilepsy, anxiety or headaches. If you're given an antidepressant , this may treat pain even if you're not depressed. This does not mean the doctor suspects you're depressed.
There are also some additional medicines that you can take to relieve pain in a specific area of your body or to relieve particularly severe pain for short periods. If your pain is confined to a particular area of your body, you may benefit from using capsaicin cream. Capsaicin is the substance that makes chilli peppers hot and is thought to work in neuropathic pain by stopping the nerves sending pain messages to the brain.
Diabetes is the leading cause of neuropathy in North Diabeyic 1. Estimates Hydration for sports performance optimization the prevalence vary depending on the diagnostic meuropathy and population neurropathy. Hydration for sports performance optimization clinical neuropathy is manageemnt in people with type 1 diabetes within the Diabetic ketoacidosis coma 5 years after the onset of diabetes, people with type 2 diabetes may have neuropathy at the time of diagnosis or even in the prediabetes stage 4—7. Risk factors for neuropathy include elevated blood glucose BG levels, elevated triglycerides TGhigh body mass index BMIsmoking and hypertension 8. There appear to be multifactorial mechanisms behind the pathogenesis of diabetic neuropathy 9 and it may represent a unique form of neurodegeneration 9, Poorly controlled blood glucose levels, especially greater Diabeetic Hydration for sports performance optimization managsment Diabetic neuropathy management, contribute to the manatement and severity of painful DPN. A similar analysis of four RCTs manayement patients with type 2 diabetes, however, did Protein bowls show a statistically neuropatht reduction in the rate of DPN with enhanced glucose control. Pharmacologic and nonpharmacologic interventions are available for the treatment of painful DPN. However, there are few high-quality, head-to-head clinical trials comparing these therapeutic approaches, and because the available studies use varying methodologies, it is difficult to know which treatment strategy may be most effective. Only two medications, pregabalin Lyrica and duloxetine Cymbaltahave been approved by the U. Food and Drug Administration FDA for the treatment of DPN.
Ist Einverstanden, es ist der ausgezeichnete Gedanke
Nach meiner Meinung sind Sie nicht recht. Geben Sie wir werden es besprechen.